Trial Profile
A Multienter, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide (62.5mcg) Once-daily to Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide (125mcg) Once-daily to Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks With COPD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Umeclidinium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 29 Jun 2019 Results of post hoc analysis of exploratory genome-wide genetic analysis from 10 trials (NCT01772134, NCT01772147, NCT00633217, NCT01817764, NCT01879410, NCT01822899, NCT01323621, NCT01342913, NCT01323634, and NCT01706328)published in the Respiratory Medicine
- 06 Sep 2018 Results (n=1637) of integrated post-hoc analysis of 4 trials (NCT01772134, NCT01772147, NCT01957163, NCT02119286) published in the Advances in Therapy
- 24 May 2017 Results (n=1637) of pooled post hoc analysis (AC4116135, NCT01772134; AC4116136, NCT01772147; 200109, NCT01957163; and 200110, NCT02119286) presented at the 113th International Conference of the American Thoracic Society